SWOG clinical trial number
CTSU/EAA181

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Open
Abbreviated Title
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Activated
10/27/2020

Research committees

Myeloma

Other Study Materials

Other Clinical Trials

S2213
SWOG Clinical Trial Number

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Research Committee(s)
Myeloma
Activated
12/01/2023
4% Accrual
Accrual
4%
Open
Phase
S2209
SWOG Clinical Trial Number

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance

Research Committee(s)
Myeloma
Activated
05/30/2023
17% Accrual
Accrual
17%
Open
Phase
S2005
SWOG Clinical Trial Number

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)

Research Committee(s)
Myeloma
Activated
06/24/2021
17% Accrual
Accrual
17%
Open
Phase